Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.
Hjorth-Hansen H, Stentoft J, Richter J, Koskenvesa P, Höglund M, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Gruber FX, Stenke L, Eriksson KM, Markevärn B, Lübking A, Vestergaard H, Udby L, Bjerrum OW, Persson I, Mustjoki S, Olsson-Strömberg U. Hjorth-Hansen H, et al. Among authors: stenke l. Leukemia. 2016 Sep;30(9):1853-60. doi: 10.1038/leu.2016.121. Epub 2016 May 2. Leukemia. 2016. PMID: 27133821 Clinical Trial.
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
Axdorph U, Stenke L, Grimfors G, Carneskog J, Hansen J, Linder O, Ljungman P, Löfvenberg E, Malm C, Simonsson B, Turesson I, Vilén L, Udén AM, Björkholm M; Swedish CML Group. Axdorph U, et al. Among authors: stenke l. Br J Haematol. 2002 Sep;118(4):1048-54. doi: 10.1046/j.1365-2141.2002.03765.x. Br J Haematol. 2002. PMID: 12199784 Free article. Clinical Trial.
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
Gruber A, Björkholm M, Brinch L, Evensen S, Gustavsson B, Hedenus M, Juliusson G, Löfvenberg E, Nesthus I, Simonsson B, Sjo M, Stenke L, Tangen JM, Tidefelt U, Udén AM, Paul C, Liliemark J. Gruber A, et al. Among authors: stenke l. Leuk Res. 2003 Apr;27(4):323-8. doi: 10.1016/s0145-2126(02)00181-9. Leuk Res. 2003. PMID: 12531223 Clinical Trial.
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up.
Simonsson B, Oberg G, Bjoreman M, Bjorkholm M, Carneskog J, Karlsson K, Gahrton G, Grimfors G, Hast R, Karle H, Linder O, Ljungman P, Nielsen JL, Nilsson J, Lofvenberg E, Malm C, Olsson K, Olsson-Stromberg U, Paul C, Stenke L, Stentoft J, Turesson I, Udén AM, Wahlin A, Vilén L, Weis-Bjerrum O. Simonsson B, et al. Among authors: stenke l. Acta Haematol. 2005;113(3):155-62. doi: 10.1159/000084445. Acta Haematol. 2005. PMID: 15870485 Clinical Trial.
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.
Olsson-Strömberg U, Höglund M, Björkholm M, Braide I, Carlson K, Gahrton G, Grimfors G, Hast R, Lerner R, Linder O, Ljungman P, Löfvenberg E, Malm C, Nilsson PG, Paul C, Rödjer S, Stenke L, Tidefeldt U, Turesson I, Uden AM, Wahlin A, Vilen L, Winqvist I, Zettervall O, Oberg G, Simonsson B. Olsson-Strömberg U, et al. Among authors: stenke l. Leuk Lymphoma. 2006 Sep;47(9):1768-73. doi: 10.1080/10428190600611117. Leuk Lymphoma. 2006. PMID: 17064986
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y; IRIS (International Randomized Interferon vs STI571) Study Group. Larson RA, et al. Blood. 2008 Apr 15;111(8):4022-8. doi: 10.1182/blood-2007-10-116475. Epub 2008 Feb 6. Blood. 2008. PMID: 18256322 Free article. Clinical Trial.
131 results